•  home page
  •  location & contact
  • Español
entrechem entrechem
  • about us
    • founders
    • key personnel
    • funding
    • strategy
  • pipeline
    • pipeline chart
    • EC-8042
    • EC-70124
  • technology
    • natural products
    • synthetic biology
    • biocatalysis
      • DA · enantiomerically pure chiral diamines
      • AA · enantiomerically pure chiral amino alcohols
      • IA · enantiomerically pure chiral amino indanes
  • collaborations
    • scientific collaborators
    • collaborative projects
  • publications
    • EC-8042
    • EC-70124
    • biocatalysis
    • synthetic biology
  • news
entrechem entrechem
  • about us
    • founders
    • key personnel
    • funding
    • strategy
  • pipeline
    • pipeline chart
    • EC-8042
    • EC-70124
  • technology
    • natural products
    • synthetic biology
    • biocatalysis
      • DA · enantiomerically pure chiral diamines
      • AA · enantiomerically pure chiral amino alcohols
      • IA · enantiomerically pure chiral amino indanes
  • collaborations
    • scientific collaborators
    • collaborative projects
  • publications
    • EC-8042
    • EC-70124
    • biocatalysis
    • synthetic biology
  • news
May 30

EntreChem participates in the ERA-Co-Biotech project «MISSION»

  • 30 May, 2018
  • Projects
EntreChem, 2 European Universities and Novartis to cooperate in the project

“MISSION: Streamlined Streptomyces cell factories for industrial production of valuable natural products.”

The European Commission has awarded €1.8M to the ERA-CoBiotech project “MISSION – Streamlined Streptomyces cell factories for industrial production of valuable natural products.” The project belongs to the ERA-Net Cofund on Biotechnologies (under the Framework Programme Horizon 2020), and it aims to enable a tailor-optimised production microbial host for valuable bioactive compounds and their downstream development as pharmaceuticals.

Professor Dr. Andriy Luzhetskyy, from the Department of Pharmacy, University of Saarland (Germany), coordinates the project. Academic partners include the Helmholtz- Zentrum für Infektionsforschung HZI/HIPS (also in Saarbrucken) and the University of Ljubljana (Slovenia). EntreChem and Novartis are the two industrial partners participating in the consortium.

MISSION is an innovative knowledge- and industry-driven value chain to produce valuable natural products by using streamlined Streptomyces rimosus cell factories.  Natural products cover a unique chemical space, particularly for the development of antibiotics and anticancer drugs. Actinomycetes are the richest source of natural products, and therefore a class of bacteria of great interest for human health. Despite the huge number of novel compounds discovered so far, the supply of sufficient amounts is a significant bottleneck that hampers drug development. MISSION will create a robust natural products supply platform based on the powerful industrial oxytetracycline overproducer Streptomyces rimosus.

The concept integrates systems and synthetic biology with bioinformatics and process engineering into a purpose-driven and engineering workflow. Multi-omics analysis of this strain will deliver key insights for targeted optimization into superior chassis. During development, the iterative and interactive combination of carefully tailored experimental and computer-modelling approaches will support the prediction of multi-combinatorial genetic traits to develop a superior microbial chassis. A full range of new synthetic parts, such as fine-tuned promoters, terminators and regulatory circuits as well as cutting-edge CRISPR/Cas9 genetic engineering will be developed for an exact, marker-less and fast translation of identified, desired features into a clear genetic language, operated by the newly created S. rimosus cells. In addition to biosynthetic power, project will consider cellular genetic stability, process tolerance and robustness by pre-early integration of expected needs from industrial partners into the design process.

MISSION is an innovative knowledge- and industry-driven value chain to produce valuable natural products by using streamlined Streptomyces rimosus cell factories.

EntreChem SL is a Spanish spin off from the University of Oviedo, and its shareholders include original co-founders and local family offices. Private financing is complemented by public funds from MINECO, IDEPA, and the 7FP and H2020 programs from the European Union.

More information:
Prof. Dr. Andriy Luzhetsky: andriy.luzhetskyy@uni-saarland.de, +49 302 70215
Dr. Francisco Morís: fmv@entrechem.com, +34 985 259 021

latest news

  • AI-Therapeutics acquires the preclinical drugs EC-8042 and EC-70124 from EntreChem SL
  • EC-8042 targets SWI/SNF complex vulnerabilities and induces epigenetic reprogramming and permanent cures in rhabdoid tumor
  • EntreChem participates in the ERA-Co-Biotech project «MISSION»

categories

  • Agreements
  • Financing
  • Projects
  • Publications
  • Research
  • Other

archive

EntreChem, S.L.

Vivero Ciencias de la Salud,
c/ Colegio Santo Domingo de Guzmán s/n,
33011 Oviedo, Spain

info@entrechem.com

pipeline  /  chart
· EC-8042
· EC-70124

scientific collaborators
collaborative projects

  • about us
  • technology
  • publications
  • news
Copyright © 2023 EntreChem, S.L. All rights reserved.
  • privacy policy
  • usage policy
  • cookies policy

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

Privacy Overview
entrechem

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!

Cookie Policy

You can consult our cookies policy for more information.